#United States #Sacramento #Headlands Research #Clinical Trials Research #Cardiometabolic Trials

Headlands Research Expands Its California Operations

Headlands Research has made a significant move by acquiring Clinical Trials Research (CTR), a prominent clinical research organization based in Sacramento and Lincoln, California. This acquisition is a strategic effort to broaden Headlands' capabilities and to enhance its reputation as a leading clinical trial site network. The new sites will be branded as Headlands Research - Sacramento and Headlands Research - CTR Lincoln.

The acquisition of CTR is especially noteworthy due to its long history and established reputation in the field of clinical trials. With over 25 years of experience, CTR has been a trusted name in conducting clinical trials across various cardiometabolic conditions such as high cholesterol, hypertension, and type 2 diabetes. Not only has it completed more than 300 Phase I-IV clinical trials, but it has also developed a strong relationship with sponsors and sponsors’ networks, ensuring that research is conducted with high standards of quality and speed.

Kyle Burtnett, the CEO of Headlands Research, highlighted the strategic advantages of this acquisition: “CTR brings something distinct in an acquisition; two established sites with a history of trust and excellence in research. By integrating their expertise with our infrastructure, we are raising the bar for what our collaborations with pharmaceutical companies and Contract Research Organizations (CROs) can achieve.” This synergy aims not only to enhance operational capabilities but also to provide pharmaceutical companies with a reliable partner in the cardiometabolic therapeutics domain.

Dr. Jeffrey D. Wayne, who has been with CTR since 1992, will continue to lead the operations at the CTR Lincoln site. A board-certified internist with a rich background in various health conditions, Dr. Wayne’s leadership promises to maintain the high standards that CTR has set over the decades. He poses, “Joining Headlands Research provides us with the necessary infrastructure and network to enhance our research efforts, reach more patients, and maintain the quality expected by our sponsors.”

This acquisition marks a significant step for Headlands Research as it aims to offer expanded therapeutic areas and innovative solutions to challenges in clinical research. With a broad range of experience in managing clinical trials, CTR has been recognized for its rapid study startup and a high rate of patient recruitment, essential factors that contribute to successful clinical outcomes.

The addition of the Sacramento and Lincoln sites allows Headlands Research to not only grow its geographical footprint but also taps into a rich pool of diverse patient populations, essential for clinical research to be reflective of real-world scenarios. Headlands operates with the mission to improve lives through the advancement of innovative medical therapies, and this strategic acquisition is a major leap toward fulfilling that mission. The company’s ability to conduct trials across several therapeutic areas, bolstered by CTR's expertise, positions it as an increasingly important player in clinical research networks.

As Headlands Research moves forward with this acquisition, it remains committed to enhancing its partnerships with sponsors and CROs, thereby paving the way for a future where innovative medical therapies can rapidly move from research settings into the hands of patients in need. To stay updated on Headlands Research and its initiatives, interested stakeholders can visit their website or follow their progress on LinkedIn.

By expanding their resources and enhancing collaboration within the clinical trial community, Headlands Research is poised to play a crucial role in addressing the growing need for efficient, high-quality clinical trials in the ever-evolving landscape of healthcare.